Premium
Monitoring for the metabolic side effects of second‐generation antipsychotic medications: Psychiatrists' views and practices
Author(s) -
Abdulhaq Bayan,
Dardas Latefa A.,
Sami Omar
Publication year - 2021
Publication title -
perspectives in psychiatric care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.538
H-Index - 35
eISSN - 1744-6163
pISSN - 0031-5990
DOI - 10.1111/ppc.12679
Subject(s) - medicine , antipsychotic , metabolic syndrome , family medicine , psychiatry , obesity , schizophrenia (object oriented programming)
Abstract Purpose The aims of this study were to explore (1) the knowledge, attitudes, practices, and adherence of psychiatrists in Jordan regarding published guidelines for metabolic monitoring of patients taking second‐generation antipsychotics (SGAs), and (2) their perceived barriers to metabolic screening. Methods The study utilized a cross‐sectional survey. Data were collected from 91 psychiatrists using a self‐administered questionnaire. Findings Almost 74% of psychiatrists reported they were aware of metabolic screening guidelines for patients taking SGA. However, the results of their assessment practices revealed a lack of adherence to these guidelines. Reported barriers to metabolic screening were the financial burden on the family and lack of family and patient compliance with recommendations of monitoring. Practice Implications Metabolic side effects of SGAs are important in Arab countries, where baseline levels of obesity and metabolic syndrome are already high in the general population. By virtue of their close proximity to patients, nurses are ideally placed to monitor how patients perceive SGAs and to provide information, advice, and counseling support.